{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"106-997-476-401-610","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"106-997-476-401-610","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11681,"type":"PATENT","title":"Weizmann Institute of Science - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":8051,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8337,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately:weizma* inst*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 8079
Search Applicants and Owners separately:weizma* inst*
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 8079
a) contacting a test sample obtaining from a subject with an antibody having specific binding affinity for a human Beclin-1 phosphorylated at residue Thr 119, or an antigen binding fragment thereof, under conditions such that a complex can form between phosphorylated Beclin-1 and the antibody and quantifying the amount of said complex, thereby quantifying the amount of phosphorylated Beclin-1 in the biological test sample; and
b) comparing the amount of phosphorylated Beclin-1 in said biological test sample to a standard or control sample; wherein a reduced amount or absence of phosphorylated Beclin-1 in said biological test sample relative to the standard or control sample is indicative of cancer in said test sample."],"number":3,"annotation":false,"claim":true,"title":false},{"lines":["The method according to claim 3, wherein the amount of phosphorylated Beclin-1 is determined by a method selected from the group consisting of immunohistochemistry, immunostaining, immunofluorescence and western blot assay; or wherein the test sample is from a human subject; or wherein said biological test sample is a tissue sample, preferably wherein the tissue sample is derived from the breast, pancreas, stomach, liver, secretory gland, bladder, lung, skin, prostate gland, ovary, cervix, uterus, brain, eye, connective tissue, bone, muscles or vasculature; or wherein the biological test sample is a suspected tumor sample, preferably wherein the tumor sample is selected from the group consisting of a breast tumor, a lung carcinoma, a colon carcinoma, a cervical carcinoma, an adenocarcinoma, a melanoma, a leukemia, a lymphoma, a glioma, a neuroblastoma, a retinoblastoma and a sarcoma; or wherein the biological test sample is a biological fluid, preferably wherein the biological fluid is selected from the group consisting of blood, serum and lymph; or further comprising the step of sequencing the gene encoding Beclin-1 in said biological test sample, wherein a mutation at position Thr 119 is indicative of cancer."],"number":4,"annotation":false,"claim":true,"title":false},{"lines":["A method for detecting a predisposition to cancer in a subject, comprising obtaining a DNA sample from the subject, and determining whether an alteration is present in the sequence encoding Beclin-1, wherein a mutation at position Thr 119 is indicative of a predisposition to cancer."],"number":5,"annotation":false,"claim":true,"title":false},{"lines":["A human Beclin-1 variant, wherein threonine at position 119 of said human Beclin-1 variant is substituted with a phospho-mimicking residue. preferably wherein said phospho-mimicking residue is a glutamic acid residue as set forth in SEQ ID NO:2; or wherein said phospho-mimicking residue is an aspartic acid as set forth in SEQ ID NO:3. more preferably wherein said variant is capable of inducing or enhancing autophagy; or wherein said variant is capable of restoring cell growth control."],"number":6,"annotation":false,"claim":true,"title":false},{"lines":["An isolated polynucleotide encoding the human Beclin-1 variant of claim 6."],"number":7,"annotation":false,"claim":true,"title":false},{"lines":["A recombinant polynucleotide construct comprising the isolated polynucleotide according to claim 7 operably linked to a transcription regulating sequence."],"number":8,"annotation":false,"claim":true,"title":false},{"lines":["A vector comprising the isolated polynucleotide according to claim 7, preferably wherein said vector is a plasmid or a virus."],"number":9,"annotation":false,"claim":true,"title":false},{"lines":["A host cell transformed with a polynucleotide according to claim 7."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising as an active ingredient the recombinant polynucleotide construct of claim 8."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["A method for treating cancer or inhibiting tumor progression in a subject in need thereof comprising expressing in cells of the subject a Beclin-1 variant according to claim 6 that induces or enhances autophagy, thereby treating cancer in said subject. preferably comprising administering into the cells ex vivo a therapeutically effective amount of a recombinant polynucleotide construct according to claim 8; or wherein said subject has a tumor characterized by significantly reduced expression or activity of death associated protein kinase (DAPk) in at least a portion of the cells of the tumor relative to the expression or activity of DAPk in a cell of a healthy subject; or wherein said subject has a tumor characterized by significantly reduced expression of wild type Beclin-1 as set forth in SEQ ID NO:1 in at least a portion of the cells of the tumor relative to the expression of said wild type Beclin-1 in a cell of a healthy subject; or wherein the human subject is selected from the group consisting of a subject displaying pathology resulting from cancer, a subject suspected of displaying pathology resulting from cancer, and a subject at risk of displaying pathology resulting from cancer."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["A method of selectively inducing, enhancing or promoting autophagy in target cells, comprising the step of exposing the target cells in vitro to the isolated polynucleotide of claim 7 in an amount sufficient to induce autophagy; preferably wherein said target cells are cells in which the expression or activity of DAPk is absent or significantly reduced; or wherein said target cells comprise mutated human Beclin-1 unable to induce autophagy; or wherein said target cell is a cancer cell."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["A recombinant polynucleotide construct according to claim 8 for treating cancer or inhibiting tumor progression in a subject; preferably wherein said subject has a tumor characterized by significantly reduced expression of wild type Beclin-1 as set forth in SEQ ID NO:1 in at least a portion of the cells of the tumor relative to the expression of said wild type Beclin-1 in a cell of a healthy subject."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["A kit for analyzing the level of Beclin-1 that is phosphorylated at position Thr119 in a biological test sample, comprising an antibody having specific binding affinity for a human Beclin-1 phosphorylated at residue Thr 119, or an antigen binding fragment thereof and instructions for performing the analysis, wherein the kit is identified for diagnosing cancer."],"number":15,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}